XML 34 R23.htm IDEA: XBRL DOCUMENT v3.25.2
STOCK OPTIONS AND WARRANTS
 6 Months Ended
Jun. 30, 2025
STOCK OPTIONS AND WARRANTS  
STOCK OPTIONS AND WARRANTS

NOTE 16 – STOCK OPTIONS AND WARRANTS

 

Omnibus Equity Incentive Plan

 

On September 19, 2022, the Company held a Board of Directors meeting, whereas, the Board of Directors had elected to adopt an Omnibus Equity Incentive Plan (the “2022 Plan”), that includes reserving 200,000 shares of common stock eligible for issuance under the 2022 Plan to be registered on a Form S-8 Registration Statement with the SEC. The 2022 Plan is designed to enable the flexibility to grant equity awards to the Company’s officers, employees, non-employee directors and consultants and to ensure that it can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. According to the Proxy Statement filed with the SEC on October 20, 2022 the 2022 Plan received final approval by the Company’s stockholders at the Annual Meeting of Stockholders held on December 2, 2022.

 

On April 3, 2023, the Company approved incentive stock awards for the CFO, certain officers and directors and other employees of the Company. The awards are in the form of restricted stock and will vest in two parts: 50% on October 2, 2023 and 50% on October 2, 2024. For the three and six-month periods ended June 30, 2025 and 2024, the Company recorded share-based compensation expense of $0 and $108,297 and $0 and $216,889, respectively, in connection with the “2022 Plan.”

On August 21, 2023, the Board adopted, subject to stockholder approval, the Cosmos Health Inc. 2023 Omnibus Equity Incentive Plan (the “2023 Plan”). The 2023 Plan is designed to enable the flexibility to grant equity awards to our officers, employees, non-employee directors and consultants and to ensure that we can continue to grant equity awards to eligible recipients at levels determined to be appropriate by the Board and/or the Compensation Committee. Subject to certain adjustments (as provided in Section 4.2 of the 2023 Plan) and exception (as provided in Section 5.6(b) of the 2023 Plan), the maximum number of shares reserved for issuance under the Plan (including incentive share options) is 2,500,000 shares. The 2023 Plan was approved by the Company’s stockholders at the Annual Meeting of Stockholders held on September 18, 2023. As of June 30, 2025, no shares remained reserved and available for future issuance under the Company's 2023 Plan.

 

On September 16, 2024, the Company’s Board of Directors approved incentive stock awards for the CEO, the CFO, certain officers and directors and other key employees of the Company pursuant to the 2023 Plan. The awards are in the form of restricted stock and will vest in two parts: 50% on September 16, 2025 and 50% on September 16, 2026. A total of 2,500,000 shares were awarded during the three and six month periods ended June 30, 2025, the Company recorded share-based compensation expense of $314,760 and $626,062, respectively, in connection with the “2023 Plan”. The expense was recorded in accordance with ASC 718 (Compensation—Stock Compensation) and is included in the Company’s Consolidated Statement of Operations.

 

Warrant Anti-Dilution Adjustment and Deemed Dividend

 

As of June 30, 2025, there were 12,926,506 warrants outstanding and 12,913,172 warrants exercisable with 12,913,172 warrants having expiration dates from May 2026 through October 2029 and 13,334 warrants with no expiration date.

 

A summary of the Company’s warrant activity for the nine months ended June 30, 2025 and the year ending December 31, 2024 is as follows:

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

Weighted

 

 

Average

 

 

 

 

 

 

 

Average

 

 

Remaining

 

 

Aggregate

 

 

 

Number of

 

 

Exercise

 

 

Contractual

 

 

Intrinsic

 

Warrants

 

Shares

 

 

Price

 

 

Term

 

 

Value

 

Balance Outstanding, January 1, 2024

 

 

8,561,476

 

 

$3.91

 

 

 

4.64

 

 

$18,801

 

Granted

 

 

9,748,252

 

 

 

0.95

 

 

 

 

 

 

 

 

 

Forfeited

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

(4,874,126 )

 

 

-

 

 

 

-

 

 

 

-

 

Expired

 

 

(509,096 )

 

 

-

 

 

 

-

 

 

 

-

 

Balance Outstanding, December 31, 2024

 

 

12,926,506

 

 

$2.63

 

 

 

3.24

 

 

$8,920

 

Granted

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Forfeited

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Exercised

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Expired

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Balance Outstanding, June 30, 2025

 

 

12,926,506

 

 

 

2.63

 

 

 

2.75

 

 

 

5,600

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Exercisable, June 30, 2025

 

 

12,913,172

 

 

 

2.63

 

 

 

2.75

 

 

 

-